Abstract Details

Title Abstract: Fast Neuro - Expedited Access to Neurology Clinic

Topic General Neurology

Presentation(s) General Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 042

Objective To reduce unburden the emergency room and inpatient general neurology teams of neurology patient care, while expediting outpatient access.

Background Emergency room and hospital overcrowding, combined with insufficient access to neurology clinics, can adversely affect healthcare institution functionality. We therefore piloted a rapid-referral program from the emergency room to neurology clinic to improve patient throughput later extended into primary care.

Design/Methods We created a Fast Neuro pool at UCLA accessible from the emergency room and call center where all outside neurology calls and referrals are reviewed. All requests were routed to a pool for triage and evaluation scheduling. Surveys were sent to Neurology residents and attendings to assess effects at 3 and 6 months.

Results Over 12 months, 170 patients were referred to Fast Neuro, 57% from UCLA and 24% from extramural emergency departments, 19% established patients. Referrals were seen within 7 days of request and 15 days of initial presentation, compared with prior wait time exceeding 40 days. 89% of residents felt Fast Neuro patients did not detract from their clinic experience, 77% indicated no increase in patient care difficulty, and all stated Fast Neuro patients helped fill cancelled appointments. All attendings agreed in each category. We extended this process to internal medicine, improving access to General Neurology.

Conclusions The Fast Neuro model improved emergency room throughput and allowed urgent evaluations within 15 days of Emergency room presentation without compromising quality of clinic cases, in-patient team utilization, or significantly increasing Neurology clinic workload. Future directions include scaling this process further by incorporating with the Internal Medicine department at UCLA.

Authors/Disclosures
Shuvro Roy, MD (University of Washington) PRESENTER	Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Roy has received research support from The Siegel Rare Neuroimmune Association.
Melissa Reider-Demer, DNP, MN, CNP (UCLA Medical Group)	Dr. Reider-Demer has nothing to disclose.
Inna Keselman, MD, PhD (UCLA)	Dr. Keselman has nothing to disclose.
Shuvro Roy, MD (University of Washington)	Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Roy has received research support from The Siegel Rare Neuroimmune Association.

��ɫ��

��ɫ��